Asunto(s)
Atresia de las Coanas/genética , Labio Leporino/genética , Fisura del Paladar/genética , Displasia Ectodérmica/genética , Anomalías del Ojo/genética , Párpados/anomalías , Mutación , Enfermedades de la Piel/genética , Piel/patología , Factores de Transcripción/genética , Proteínas Supresoras de Tumor/genética , Atresia de las Coanas/diagnóstico , Labio Leporino/diagnóstico , Fisura del Paladar/diagnóstico , Análisis Mutacional de ADN , Displasia Ectodérmica/diagnóstico , Anomalías del Ojo/diagnóstico , Femenino , Predisposición Genética a la Enfermedad , Humanos , Lactante , Recién Nacido , Fenotipo , Enfermedades de la Piel/diagnósticoAsunto(s)
Eritrodermia Ictiosiforme Congénita/tratamiento farmacológico , Ictiosis Lamelar/tratamiento farmacológico , Queratolíticos/uso terapéutico , Errores Innatos del Metabolismo Lipídico/tratamiento farmacológico , Enfermedades Musculares/tratamiento farmacológico , Ácidos Nicotínicos/uso terapéutico , Adolescente , Femenino , Humanos , Eritrodermia Ictiosiforme Congénita/fisiopatología , Ictiosis Lamelar/fisiopatología , Errores Innatos del Metabolismo Lipídico/fisiopatología , Enfermedades Musculares/fisiopatología , Crema para la Piel/uso terapéutico , Tomografía de Coherencia Óptica , Pérdida Insensible de AguaRESUMEN
Human papillomavirus (HPV) infections are the most common sexually transmitted diseases leading to genital warts. Developing lesions start off as small papules, which then grow larger and protrude, eventually coalescing into plaque-like formations. The aim of this study was to evaluate the efficacy of diode laser coagulation as a treatment for genital warts relative to their number, size, localisation, and recurrence rate. Altogether, 45 patients were evaluated in this study. Patients were initially assigned to one of two groups, depending on the size and number of their genital warts, and received a maximum of two laser treatments. Patients were assessed up to three months after intervention. A cure was defined as the complete removal of condylomata. In Group I, 84% of the patients (21/25) were free of recurrence after three months (last follow-up visit). In Group II, 60% of the patients were free of recurrence after three months (12/20 patients); 25% after the first and 35% after the second treatment. Overall, a cure rate of 73% was achieved (33/45 patients). By splitting the laser treatment for multiple, extensive, and/or coalescing genital warts into two sessions, thereby being less destructive to the surrounding tissue, it was possible to achieve comparable cure rates between the two groups. This study indicates that laser treatment is an effective therapy option. Further studies including larger patient cohorts are necessary to ultimately confirm the advantages of laser treatment.
Asunto(s)
Condiloma Acuminado/cirugía , Condiloma Acuminado/virología , Terapia por Láser/métodos , Láseres de Semiconductores/uso terapéutico , Enfermedades de Transmisión Sexual/cirugía , Adulto , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Alemania , Humanos , Masculino , Persona de Mediana Edad , Infecciones por Papillomavirus/diagnóstico , Infecciones por Papillomavirus/cirugía , Estudios Prospectivos , Recurrencia , Medición de Riesgo , Arabia Saudita , Enfermedades de Transmisión Sexual/prevención & control , Factores de Tiempo , Resultado del TratamientoRESUMEN
Treatment of children diagnosed with atopic dermatitis (AD) is an art. Age-dependent barrier function, skin physiology, body surface:weight ratio, the compliance of patient and caregivers, and legal considerations related to the license status of topical and systemic drugs must be considered. Mild to moderate AD can usually be treated sufficiently with a personalized regimen of emollients and topical anti-inflammatory therapy consisting of topical corticosteroids (TCSs) or topical calcineurin inhibitors. Emollients containing bacterial lysates, tailored wet wrap regimen, and proactive therapy with tacrolimus ointment or some TCSs are new developments in the field. Severe AD may need systemic therapy, but all currently available systemic agents for severe AD are either not licensed for children or not advisable on the long term, or both. Therapeutic patient education based on structured, interactive sessions with patients or caregivers and a multidisciplinary team is highly effective. This publication summarizes the current therapeutic options used in the pediatric AD population.